

ASX ANNOUNCEMENT

ASX: 1AI | 28 April 2026

Algorae and Zydus Enter Exclusive Commercial Agreement for 10 Products across ANZ Markets

Highlights

- **Algorae enters commercial & licensing agreement with Zydus Lifesciences Ltd (NSE: ZYDUSLIFE; BSE: 532321)**
- **Products intended for commercialisation in Australia and New Zealand, subject to applicable regulatory approvals**
- **Collaboration supports the parties shared objective of expanding access to high quality medicines in regulated markets**

Algorae Pharmaceuticals Ltd (ASX: 1AI) ("Algorae" or "Company") advises that it has entered into **exclusive commercial and licensing agreement for 10 products** with **Zydus Lifesciences Ltd** (NSE: ZYDUSLIFE; BSE: 532321) for the Australian and New Zealand markets.

The agreement establishes a framework under which the parties will collaborate on the introduction of a portfolio comprising injectable, oral and specialty pharmaceutical products across hospital and community care channels. The products are expected to be commercialised through Algorae's ANZ platform, subject to Therapeutic Goods Administration ("TGA") and other applicable regulatory approvals.

Commenting on the agreement, Algorae Chief Commercial Officer **Mr Vishal Shah** said the collaboration aligns strongly with the Company's commercial strategy:

"The product-specific exclusive agreement with Zydus covers a broad range of injectable, oral and specialty medicines, and supports our strategy to build a reliable, compliant portfolio for the ANZ market. The collaboration brings together complementary capabilities to support long-term portfolio development."

Product prioritisation will be undertaken jointly by the parties, taking into account regulatory pathways, supply readiness and market access considerations.

As part of the agreement, the parties completed customary commercial and technical due diligence and confirmed alignment with applicable Australian and New Zealand regulatory and market requirements.

Zydus Lifesciences Ltd, headquartered in Ahmedabad, India, is a global pharmaceutical company with manufacturing and development capabilities spanning sterile injectables, oral dosage forms, specialty formulations and complex generics, supplying medicines into regulated and emerging markets worldwide.

The collaboration strengthens Algorae's commercial platform and supports its objective of establishing a sustainable and compliant pharmaceutical supply presence in Australia and New Zealand.

Algorae Chairman **Mr David Hainsworth** said the agreement represents an important step in the Company's long-term strategy.

"This agreement strengthens Algorae's commercial platform and supports long term portfolio development in highly regulated markets. We welcome the collaboration with Zydus and the opportunities it presents for sustainable growth."

Through its wholly owned subsidiary **AlgoraeRx Pty Ltd**, the Company continues to progress commercial initiatives and will update shareholders as these advance.

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd is a fully integrated, global pharmaceutical company headquartered in Ahmedabad, India, with operations spanning 55 countries and a workforce exceeding 27,000 employees worldwide. The company operates more than 20 manufacturing facilities across India, the United States, and Brazil producing active pharmaceutical ingredients (APIs) and finished dosage forms, including sterile injectables, oral and specialty formulations, supplying products across regulated and emerging markets.

Zydus is listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE).

<https://www.zyduslife.com>

Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd

END.

Corporate and Media Enquiries

Mr David Hainsworth

Executive Chairman


E: inquiries@algoraepharma.com

About Algorae Pharmaceuticals

Algorae Pharmaceuticals Ltd (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies artificial intelligence to identify synergistic drug combinations and inform preclinical experimental design.

In parallel, Algorae operates a commercialisation business, AlgoraeRx, which sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through manufacturing partners and established distribution channels. Algorae collaborates with research institutions and industry partners to translate AI-predicted therapies and expand patient access to high-quality medicines.

For more information visit www.algoraepharma.com or follow @algoraepharma on X or LinkedIn.



Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

For personal use only